← All candidates
Two insider buys in the last year — $42.2K in all.
10 filings on record.
CATXPerspective Therapeutics, Inc.
NYSE American · Healthcare · $308.21M
$2.70
-1.10% today
Two insider buys in the last year — $42.2K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 2 buys● 5 sells◆ 20 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what CATX ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$308.21M
Float
68.3M
60% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
753.6
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Accounting Officer
Hunt Jonathan Robert
Bought $22.3K on Nov 13 — 11,000 sh @ $2.03, held direct, 18% of their stake.
1 of 1 position beat the S&P
Director
Williamson Robert F III
Bought $19.9K on Nov 12 — 9,498 sh @ $2.10, held indirect, 96% of their stake.
1 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
3 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
2 more transactions on Pro →Context
Wall St
$12.29 avg target
+355.0% vs today · 14 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q2 '26−$0.22 act+$0.05
Q1 '26−$0.25 act+$0.07
Q4 '25−$0.51 act−$0.16
Q3 '25−$0.35 act−$0.03
Coverage
Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC SaysMT Newswires · 08-11Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?Zacks · 08-04Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks · 07-29Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?Zacks · 07-16
The file stays open
10 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice